Literature DB >> 19029809

Role of the cyclin-dependent kinase 9-related pathway in mammalian gene expression and human diseases.

Gaetano Romano1, Antonio Giordano.   

Abstract

Cyclin-dependent kinase 9 (Cdk9) is a cdc2-like serine/threonine kinase. The so-called Cdk9-related pathway comprises two Cdk9 isoforms (Cdk9-42 and Cdk9-55), cyclin T1, cyclin T2a, cyclin T2b and cyclin K. The association between Cdk9 and one of its cyclin partners forms a heterodimer, which is the main component of the positive transcription elongation factor (P-TEFb). The latter stabilizes the elongation process of RNA polymerase II (polII) transcripts. Through the control of RNA polII-mediated gene expression, the Cdk9-related pathway performs an important role in several biological processes, such as cell growth, proliferation, protection from apoptosis and differentiation. Incidentally, the P-TEFb that contains the heterodimer Cdk9-cyclin T1 is also critical for HIV-1 and HIV-2 replication in human cells. A deregulation in the Cdk9-related pathway is associated with various types of human malignancies and cardiomyocytes hypertrophy. On these grounds, the characterization of Cdk9-related pathway deregulation might have a two-fold purpose: (1) the development of novel kinase inhibitors for the treatment of cancer, AIDS and cardiac hypertrophy and (2) a better understanding of the pathogenesis and progression of these maladies.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19029809     DOI: 10.4161/cc.7.23.7122

Source DB:  PubMed          Journal:  Cell Cycle        ISSN: 1551-4005            Impact factor:   4.534


  43 in total

Review 1.  RNA polymerase II elongation control.

Authors:  Qiang Zhou; Tiandao Li; David H Price
Journal:  Annu Rev Biochem       Date:  2012-03-09       Impact factor: 23.643

Review 2.  Cell cycle kinases as therapeutic targets for cancer.

Authors:  Silvia Lapenna; Antonio Giordano
Journal:  Nat Rev Drug Discov       Date:  2009-07       Impact factor: 84.694

3.  Posttranslational modifications of the retinoblastoma tumor suppressor protein as determinants of function.

Authors:  James I Macdonald; Frederick A Dick
Journal:  Genes Cancer       Date:  2012-11

Review 4.  ATR signalling: more than meeting at the fork.

Authors:  Edward A Nam; David Cortez
Journal:  Biochem J       Date:  2011-06-15       Impact factor: 3.857

5.  Isolation and functional characterization of P-TEFb-associated factors that control general and HIV-1 transcriptional elongation.

Authors:  Ruichuan Chen; Min Liu; Kai Zhang; Qiang Zhou
Journal:  Methods       Date:  2010-04-10       Impact factor: 3.608

Review 6.  The Bin3 RNA methyltransferase targets 7SK RNA to control transcription and translation.

Authors:  Michael S Cosgrove; Ye Ding; William A Rennie; Michael J Lane; Steven D Hanes
Journal:  Wiley Interdiscip Rev RNA       Date:  2012-06-27       Impact factor: 9.957

Review 7.  A role for CDK9-cyclin K in maintaining genome integrity.

Authors:  David S Yu; David Cortez
Journal:  Cell Cycle       Date:  2011-01-01       Impact factor: 4.534

8.  Functional association of Gdown1 with RNA polymerase II poised on human genes.

Authors:  Bo Cheng; Tiandao Li; Peter B Rahl; Todd E Adamson; Nicholas B Loudas; Jiannan Guo; Katayoun Varzavand; Jeffrey J Cooper; Xiaopeng Hu; Averell Gnatt; Richard A Young; David H Price
Journal:  Mol Cell       Date:  2012-01-13       Impact factor: 17.970

9.  Growth inhibition of malignant glioblastoma by DING protein.

Authors:  Markus J Bookland; Nune Darbinian; Michael Weaver; Shohreh Amini; Kamel Khalili
Journal:  J Neurooncol       Date:  2011-11-04       Impact factor: 4.130

10.  Novel Targeting of Transcription and Metabolism in Glioblastoma.

Authors:  Yu-Ting Su; Robert Chen; Herui Wang; Hua Song; Qi Zhang; Li-Yuan Chen; Hallie Lappin; Gabriel Vasconcelos; Adrian Lita; Dragan Maric; Aiguo Li; Orieta Celiku; Wei Zhang; Kristan Meetze; Thomas Estok; Mioara Larion; Mones Abu-Asab; Zhengping Zhuang; Chunzhang Yang; Mark R Gilbert; Jing Wu
Journal:  Clin Cancer Res       Date:  2017-12-18       Impact factor: 12.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.